Global Initiative Orders 120 Million Abbott, SD Biosensor COVID-19 Rapid Antigen Tests
Tests will be priced at under $5 each for low- and middle-income countries.
You may also be interested in...
Cue’s point-of-care molecular test earned an FDA emergency use authorization in June.
A resolution at the latest World Health Assembly meeting on providing universal and equitable access to COVID-19 technologies, medicines and vaccines has been adopted, along with an agreement to review the World Health Organization’s response to the crisis.
Deals give the company access to technologies to increase the accuracy of multi-cancer blood tests.